|
WO2010084160A1
(en)
|
2009-01-21 |
2010-07-29 |
Oryzon Genomics S.A. |
Phenylcyclopropylamine derivatives and their medical use
|
|
KR101736218B1
(ko)
|
2009-09-25 |
2017-05-16 |
오리존 지노믹스 에스.에이. |
라이신 특이적 디메틸라아제-1 억제제 및 이의 용도
|
|
EP2486002B1
(en)
|
2009-10-09 |
2019-03-27 |
Oryzon Genomics, S.A. |
Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
|
|
WO2011106574A2
(en)
|
2010-02-24 |
2011-09-01 |
Oryzon Genomics, S.A. |
Inhibitors for antiviral use
|
|
US9186337B2
(en)
|
2010-02-24 |
2015-11-17 |
Oryzon Genomics S.A. |
Lysine demethylase inhibitors for diseases and disorders associated with Hepadnaviridae
|
|
ES2607081T3
(es)
|
2010-04-19 |
2017-03-29 |
Oryzon Genomics, S.A. |
Inhibidores de desmetilasa específica de lisina-1 y su uso
|
|
US9006449B2
(en)
|
2010-07-29 |
2015-04-14 |
Oryzon Genomics, S.A. |
Cyclopropylamine derivatives useful as LSD1 inhibitors
|
|
LT2598482T
(lt)
|
2010-07-29 |
2018-07-10 |
Oryzon Genomics, S.A. |
Demetilazės lsd1 inhibitoriai arilciklopropilamino pagrindu ir jų medicininis panaudojimas
|
|
US9061966B2
(en)
|
2010-10-08 |
2015-06-23 |
Oryzon Genomics S.A. |
Cyclopropylamine inhibitors of oxidases
|
|
WO2012072713A2
(en)
|
2010-11-30 |
2012-06-07 |
Oryzon Genomics, S.A. |
Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
|
|
WO2012107498A1
(en)
|
2011-02-08 |
2012-08-16 |
Oryzon Genomics S.A. |
Lysine demethylase inhibitors for myeloproliferative disorders
|
|
UA114406C2
(uk)
|
2011-08-09 |
2017-06-12 |
Такеда Фармасьютікал Компані Лімітед |
Похідні циклопропанаміну як інгібітори lsd1
|
|
EP3736265A1
(en)
|
2011-10-20 |
2020-11-11 |
Oryzon Genomics, S.A. |
(hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
|
|
SI2776394T1
(sl)
|
2011-10-20 |
2019-05-31 |
Oryzon Genomics, S.A. |
Spojine (hetero)aril ciklopropilamina kot inhibitorji LSD1
|
|
US20150203453A1
(en)
|
2012-10-02 |
2015-07-23 |
Epitherapeutics Aps |
Inhibitors of histone demethylases
|
|
CN105051005B
(zh)
|
2012-10-12 |
2017-06-13 |
武田药品工业株式会社 |
环丙胺化合物及其用途
|
|
EP2740474A1
(en)
|
2012-12-05 |
2014-06-11 |
Instituto Europeo di Oncologia S.r.l. |
Cyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a
|
|
JP6514117B2
(ja)
|
2013-02-27 |
2019-05-15 |
エピセラピューティクス アーペーエス |
ヒストン脱メチル化酵素の阻害剤
|
|
WO2014194280A2
(en)
*
|
2013-05-30 |
2014-12-04 |
The Board of Regents of the Nevada System of Higher Education on behalf of the University of |
Novel suicidal lsd1 inhibitors targeting sox2-expressing cancer cells
|
|
WO2015012515A1
(ko)
*
|
2013-07-25 |
2015-01-29 |
동아에스티 주식회사 |
벤즈아미드 유도체의 제조방법, 그의 제조에 사용되는 새로운 중간체 및 상기 중간체의 제조방법
|
|
WO2015021128A1
(en)
|
2013-08-06 |
2015-02-12 |
Imago Biosciences Inc. |
Kdm1a inhibitors for the treatment of disease
|
|
WO2015123437A1
(en)
*
|
2014-02-13 |
2015-08-20 |
Incyte Corporation |
Cyclopropylamines as lsd1 inhibitors
|
|
TWI664164B
(zh)
*
|
2014-02-13 |
2019-07-01 |
美商英塞特控股公司 |
作為ｌｓｄ１抑制劑之環丙胺
|
|
WO2015123408A1
(en)
|
2014-02-13 |
2015-08-20 |
Incyte Corporation |
Cyclopropylamines as lsd1 inhibitors
|
|
PE20161573A1
(es)
*
|
2014-02-13 |
2017-01-19 |
Incyte Corp |
Ciclopropilamina como inhibidor de la lsd1
|
|
CN104042616B
(zh)
*
|
2014-02-20 |
2016-08-24 |
复旦大学附属眼耳鼻喉科医院 |
赖氨酸特异性去甲基化酶1抑制剂的应用
|
|
CN106459024B
(zh)
|
2014-04-11 |
2019-11-05 |
武田药品工业株式会社 |
环丙胺化合物及其用途
|
|
SG11201609033TA
(en)
|
2014-05-01 |
2016-11-29 |
Celgene Quanticel Res Inc |
Inhibitors of lysine specific demethylase-1
|
|
US9695180B2
(en)
|
2014-07-10 |
2017-07-04 |
Incyte Corporation |
Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
|
|
US9758523B2
(en)
|
2014-07-10 |
2017-09-12 |
Incyte Corporation |
Triazolopyridines and triazolopyrazines as LSD1 inhibitors
|
|
US9695168B2
(en)
|
2014-07-10 |
2017-07-04 |
Incyte Corporation |
Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors
|
|
WO2016007722A1
(en)
|
2014-07-10 |
2016-01-14 |
Incyte Corporation |
Triazolopyridines and triazolopyrazines as lsd1 inhibitors
|
|
CA2957947A1
(en)
|
2014-08-27 |
2016-03-03 |
Gilead Sciences, Inc. |
Compounds and methods for inhibiting histone demethylases
|
|
WO2016055935A1
(en)
*
|
2014-10-06 |
2016-04-14 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Combination of lysine-specific demethylase 1 inhibitor and thrombopoietin agonist
|
|
EA039196B1
(ru)
*
|
2014-10-08 |
2021-12-16 |
Инсайт Корпорейшн |
Циклопропиламины в качестве ингибиторов lsd1
|
|
EP3250552B1
(en)
*
|
2015-01-30 |
2019-03-27 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
|
PL3256218T3
(pl)
|
2015-02-12 |
2025-03-31 |
Imago Biosciences Inc. |
Inhibitor kdm1a i jego zastosowanie w terapii
|
|
MY191796A
(en)
|
2015-04-03 |
2022-07-15 |
Incyte Corp |
Heterocyclic compounds as lsd1 inhibitors
|
|
EP3286172B1
(en)
|
2015-04-23 |
2019-06-12 |
Constellation Pharmaceuticals, Inc. |
Lsd1 inhibitors and uses thereof
|
|
EP3090998A1
(en)
|
2015-05-06 |
2016-11-09 |
F. Hoffmann-La Roche AG |
Solid forms
|
|
WO2016198649A1
(en)
|
2015-06-12 |
2016-12-15 |
Oryzon Genomics, S.A. |
Biomarkers associated with lsd1 inhibitors and uses thereof
|
|
EP3307267B1
(en)
|
2016-06-10 |
2019-04-10 |
Oryzon Genomics, S.A. |
Multiple sclerosis treatment
|
|
WO2017013061A1
(en)
|
2015-07-17 |
2017-01-26 |
Oryzon Genomics, S.A. |
Biomarkers associated with lsd1 inhibitors and uses thereof
|
|
KR102710120B1
(ko)
*
|
2015-08-12 |
2024-09-27 |
인사이트 홀딩스 코포레이션 |
Lsd1 저해제의 염
|
|
EP3341353A1
(en)
|
2015-08-27 |
2018-07-04 |
Genentech, Inc. |
Therapeutic compounds and methods of use thereof
|
|
US10059668B2
(en)
*
|
2015-11-05 |
2018-08-28 |
Mirati Therapeutics, Inc. |
LSD1 inhibitors
|
|
WO2017091592A1
(en)
|
2015-11-25 |
2017-06-01 |
Genentech, Inc. |
Substituted benzamides useful as sodium channel blockers
|
|
WO2017097865A1
(en)
*
|
2015-12-07 |
2017-06-15 |
Istituto Europeo Di Oncologia |
Combination of caloric restriction (cr) or igf1/insulin receptor inhibitor with lsd1 inhibitor
|
|
KR102720551B1
(ko)
*
|
2015-12-29 |
2024-10-21 |
미라티 테라퓨틱스, 인크. |
Lsd1 억제제
|
|
EP3397756B1
(en)
|
2015-12-30 |
2023-03-08 |
Novartis AG |
Immune effector cell therapies with enhanced efficacy
|
|
AU2017233898B2
(en)
|
2016-03-15 |
2022-12-15 |
Oryzon Genomics, S.A. |
Combinations of LSD1 inhibitors for use in the treatment of solid tumors
|
|
KR102646126B1
(ko)
|
2016-03-15 |
2024-03-11 |
오리존 지노믹스 에스.에이. |
혈액 악성 종양의 치료를 위한 lsd1 억제제의 조합물
|
|
ES3042059T3
(en)
|
2016-03-16 |
2025-11-18 |
Oryzon Genomics Sa |
Methods to determine kdm1a target engagement and chemoprobes useful therefor
|
|
CN107200706A
(zh)
*
|
2016-03-16 |
2017-09-26 |
中国科学院上海药物研究所 |
一类氟取代的环丙胺类化合物及其制备方法、药物组合物和用途
|
|
WO2017172802A1
(en)
|
2016-03-30 |
2017-10-05 |
Genentech, Inc. |
Substituted benzamides and methods of use thereof
|
|
PE20190377A1
(es)
|
2016-04-22 |
2019-03-08 |
Incyte Corp |
Formulaciones de un inhibidor de lsd 1
|
|
CN107459476B
(zh)
*
|
2016-06-03 |
2022-06-24 |
中国科学院上海药物研究所 |
反吲哚啉环丙胺类化合物及其制备方法、药物组合物和用途
|
|
WO2018020366A1
(en)
|
2016-07-26 |
2018-02-01 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Crystalline (r)-mandelate salt of (1r,2s)-2-phenylcyclopropylamine
|
|
SG10201610038SA
(en)
*
|
2016-07-29 |
2017-12-28 |
Apple Inc |
Systems and methods for management of asymmetrical multi-tapped battery packs
|
|
CN111194306B
(zh)
|
2016-08-16 |
2023-05-16 |
伊美格生物科学公司 |
用于制备kdm1a抑制剂的方法和过程
|
|
RU2019114964A
(ru)
|
2016-10-17 |
2020-11-17 |
Дженентек, Инк. |
Терапевтические средства и способы их применения
|
|
US20190256929A1
(en)
|
2016-11-03 |
2019-08-22 |
Oryzon Genomics, S.A. |
Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents
|
|
EP3535420A1
(en)
|
2016-11-03 |
2019-09-11 |
Oryzon Genomics, S.A. |
Biomarkers for determining responsiveness to lsd1 inhibitors
|
|
WO2018106984A1
(en)
|
2016-12-09 |
2018-06-14 |
Constellation Pharmaceuticals, Inc. |
Markers for personalized cancer treatment with lsd1 inhibitors
|
|
RU2763898C9
(ru)
*
|
2017-01-24 |
2022-03-18 |
Цспц Чжунци Фармасьютикал Текнолоджи (Шицзячжуан) Ко., Лтд. |
Ингибитор lsd1, а также способ его получения и его применение
|
|
US10793550B2
(en)
|
2017-03-24 |
2020-10-06 |
Genentech, Inc. |
4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors
|
|
WO2018197583A1
(en)
|
2017-04-26 |
2018-11-01 |
Istituto Europeo Di Oncologia |
Use of a combinational therapy of lsd1 inhibitors with p21 activators in the treatment of cancer
|
|
TWI727173B
(zh)
|
2017-05-26 |
2021-05-11 |
日商大鵬藥品工業股份有限公司 |
使用有新穎聯苯化合物之抗腫瘤效果增強劑
|
|
WO2018216800A1
(ja)
|
2017-05-26 |
2018-11-29 |
大鵬薬品工業株式会社 |
新規なビフェニル化合物又はその塩
|
|
WO2018221555A1
(ja)
|
2017-05-31 |
2018-12-06 |
大鵬薬品工業株式会社 |
Ｉｎｓｍ１の発現に基づくｌｓｄ１阻害剤の治療効果の予測方法
|
|
KR20180134675A
(ko)
*
|
2017-06-09 |
2018-12-19 |
한미약품 주식회사 |
시클로프로필아민 유도체 화합물 및 이의 용도
|
|
JP2020152641A
(ja)
*
|
2017-07-07 |
2020-09-24 |
国立研究開発法人理化学研究所 |
リジン特異的脱メチル化酵素１阻害活性を有する新規化合物、その製造方法及びその用途
|
|
MY204406A
(en)
|
2017-08-03 |
2024-08-27 |
Oryzon Genomics Sa |
Methods of treating behavior alterations
|
|
AR112900A1
(es)
|
2017-09-13 |
2019-12-26 |
Hanmi Pharm Ind Co Ltd |
Compuesto derivado de pirazol y uso de este
|
|
WO2019068326A1
(en)
|
2017-10-05 |
2019-04-11 |
Université D'aix-Marseille |
INHIBITORS OF LSD1 FOR THE TREATMENT AND PREVENTION OF CARDIOMYOPATHIES
|
|
KR20190040763A
(ko)
|
2017-10-11 |
2019-04-19 |
한미약품 주식회사 |
피라졸로피리딘 유도체 화합물 및 이의 용도
|
|
KR20190040783A
(ko)
|
2017-10-11 |
2019-04-19 |
한미약품 주식회사 |
라이신 특이적 데메틸라제-1 억제제로서의 피라졸 유도체
|
|
US11685782B2
(en)
|
2017-10-23 |
2023-06-27 |
Children's Medical Center Corporation |
Methods of treating cancer using LSD1 inhibitors in combination with immunotherapy
|
|
WO2019109095A1
(en)
*
|
2017-12-01 |
2019-06-06 |
Beth Israel Deaconess Medical Center, Inc. |
Arsenic trioxide and retinoic acid compounds for treatment of idh2-associated disorders
|
|
CN108107199B
(zh)
*
|
2017-12-21 |
2019-02-12 |
广州市进德生物科技有限公司 |
一种酶化学发光法测定尿酸的检测试剂盒
|
|
WO2019165290A1
(en)
|
2018-02-26 |
2019-08-29 |
Genentech, Inc. |
Pyridine-sulfonamide compounds and their use against pain and related conditions
|
|
EP3774801A1
(en)
|
2018-03-30 |
2021-02-17 |
F. Hoffmann-La Roche AG |
Fused ring hydro-pyrido compounds as sodium channel inhibitors
|
|
JP7450559B2
(ja)
|
2018-05-11 |
2024-03-15 |
イマーゴ バイオサイエンシーズ インコーポレイテッド |
疾患の処置のためのｋｄｍ１ａ阻害剤
|
|
TW202003490A
(zh)
|
2018-05-22 |
2020-01-16 |
瑞士商赫孚孟拉羅股份公司 |
治療性化合物及其使用方法
|
|
CN112424175B
(zh)
*
|
2018-07-20 |
2022-10-28 |
石药集团中奇制药技术（石家庄）有限公司 |
一种lsd1抑制剂的盐及其晶型
|
|
US10968200B2
(en)
|
2018-08-31 |
2021-04-06 |
Incyte Corporation |
Salts of an LSD1 inhibitor and processes for preparing the same
|
|
WO2020052647A1
(zh)
*
|
2018-09-13 |
2020-03-19 |
南京明德新药研发有限公司 |
作为lsd1抑制剂的杂螺环类化合物及其应用
|
|
CN112689638B
(zh)
*
|
2018-09-13 |
2022-11-08 |
南昌弘益药业有限公司 |
作为lsd1抑制剂的环丙胺类化合物及其应用
|
|
EP3890715A4
(en)
*
|
2018-12-04 |
2023-03-29 |
The Board Of Regents Of The University Of Texas System |
Therapeutics targeting mutant adenomatous polyposis coli (apc) for the treatment of cancer
|
|
JPWO2020138398A1
(ja)
*
|
2018-12-28 |
2021-11-04 |
国立研究開発法人理化学研究所 |
リジン特異的脱メチル化酵素１を阻害する新規化合物、その製造方法及びその用途
|
|
US12479845B2
(en)
|
2019-02-01 |
2025-11-25 |
Hanmi Pharm. Co., Ltd. |
Imidazopyridine derivative compounds and use of same
|
|
EP3907225A4
(en)
|
2019-02-01 |
2022-09-14 |
Hanmi Pharm. Co., Ltd. |
COMPOUNDS DERIVED FROM IMIDAZOPYRIDINE AND THEIR USE
|
|
CN120837494A
(zh)
|
2019-03-20 |
2025-10-28 |
奥莱松基因组股份有限公司 |
使用kdm1a抑制剂如化合物伐菲德司他治疗注意缺陷多动症的方法
|
|
BR112021016064A2
(pt)
|
2019-03-20 |
2021-10-05 |
Oryzon Genomics, S.A. |
Métodos de tratamento do transtorno de personalidade borderline
|
|
JP2022546908A
(ja)
|
2019-07-05 |
2022-11-10 |
オリゾン・ゲノミクス・ソシエダッド・アノニマ |
Ｋｄｍ１ａ阻害剤を使用した小細胞肺がんの個別化された処置のためのバイオマーカーおよび方法
|
|
WO2021058024A1
(zh)
*
|
2019-09-29 |
2021-04-01 |
南京明德新药研发有限公司 |
Lsd1抑制剂
|
|
CN115835797A
(zh)
*
|
2020-05-28 |
2023-03-21 |
耐克创新有限合伙公司 |
包括流体移动控制器和可调节足部支撑压力的足部支撑系统
|
|
EP3964204A1
(en)
|
2020-09-08 |
2022-03-09 |
Université d'Aix-Marseille |
Lsd1 inhibitors for use in the treatment and prevention of fibrosis of tissues
|
|
CN115485282B
(zh)
*
|
2021-02-09 |
2025-09-09 |
南昌弘益药业有限公司 |
一种氧氮杂螺环化合物、其盐型及其晶型
|
|
CA3231846A1
(en)
|
2021-04-08 |
2022-10-13 |
Tamara Maes |
Combinations of lsd1 inhibitors for treating myeloid cancers
|
|
CN116888122A
(zh)
*
|
2021-06-22 |
2023-10-13 |
南昌弘益药业有限公司 |
含氮氧杂螺环类化合物及其应用
|
|
CN113512031B
(zh)
*
|
2021-07-01 |
2024-01-30 |
都创(上海)医药开发有限公司 |
一种lsd1酶抑制剂tak-418中间体化合物制备方法
|
|
EP4419093A1
(en)
|
2021-10-20 |
2024-08-28 |
Queen Mary University of London |
Sequential treatments and biomarkers to reverse resistance to kinase inhibitors
|
|
GB202115017D0
(en)
|
2021-10-20 |
2021-12-01 |
Univ London Queen Mary |
Sequential treatments and biomarkers to reverse resistance to kinase inhibitors
|
|
CN119497613A
(zh)
|
2022-05-09 |
2025-02-21 |
奥莱松基因组股份有限公司 |
使用lsd1抑制剂治疗nf1-突变肿瘤的方法
|
|
EP4522136A1
(en)
|
2022-05-09 |
2025-03-19 |
Oryzon Genomics, S.A. |
Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors
|
|
AU2023385514A1
(en)
|
2022-11-24 |
2025-07-10 |
Oryzon Genomics, S.A. |
Combinations of lsd1 inhibitors and menin inhibitors for treating cancer
|
|
TW202508595A
(zh)
|
2023-05-04 |
2025-03-01 |
美商銳新醫藥公司 |
用於ｒａｓ相關疾病或病症之組合療法
|
|
WO2025034702A1
(en)
|
2023-08-07 |
2025-02-13 |
Revolution Medicines, Inc. |
Rmc-6291 for use in the treatment of ras protein-related disease or disorder
|
|
CN117164465B
(zh)
*
|
2023-09-04 |
2025-07-01 |
郑州大学 |
一种苯基环丙胺类化合物及其制备方法和应用
|
|
WO2025080946A2
(en)
|
2023-10-12 |
2025-04-17 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025240847A1
(en)
|
2024-05-17 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|